SCHEMBL5625166

SCHEMBL5625166

CC1=Nc2ccc(S(N)(=O)=O)cc2S(=O)(=O)N1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 11/20 0.56
CA2 P00918 11/20 0.56
CA9 Q16790 10/20 0.56
CA12 O43570 6/20 0.56
CA7 P43166 3/20 0.56
GLO1 Q04760 1/20 0.56
MAPT P10636 2/20 0.40
CA6 P23280 2/20 0.37
CA5A P35218 2/20 0.37
CA5B Q9Y2D0 2/20 0.37
CA3 P07451 1/20 0.37
ALOX5 P09917 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5624968 0.83 HTR2C (0.38) CA1CA2CA9CA12CA7
SCHEMBL16455556 0.78 CA12 (0.51) CA1CA2CA9CA12CA7
SCHEMBL5625365 0.78 CA2 (0.48) CA1CA2CA9CA12CA7
SCHEMBL12570063 0.78 CA2 (0.47) CA1CA2CA9CA12CA7
Diazoxide SCHEMBL28482607 0.77 CHEK1 (0.46) CA1CA2CA9CA12CA7
SCHEMBL1082083 0.75 CA12 (0.32) CA1CA2CA9CA12CA7
Diazoxide SCHEMBL41254 0.75 CHEK1 (0.51) CA1CA2CA9CA12CA7
Diazoxide SCHEMBL29384603 0.75 CHEK1 (0.51) CA1CA2CA9CA12CA7
Diazoxide SCHEMBL1725516 0.74 CHEK1 (0.50) CA1CA2CA9CA12CA7
Diazoxide SCHEMBL1726275 0.74 CHEK1 (0.50) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235548-B2 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2007-06-26 US disclosed
US-6943159-B1 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2005-09-13 US disclosed
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S. 2004-03-04 US disclosed
EP-1071426-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2001-01-31 EP disclosed
WO-1999042456-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 1999-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators GRIK4, GRIA4, GRM2 CA1 388/4885CA2 365/4885CA9 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.